Orchestra BioMed COO Sherman sells 15,000 shares
The president and chief operating officer's reported sale was made under a Rule 10b5-1 plan adopted December 18, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Orchestra BioMed Holdings, Inc. President and Chief Operating Officer Darren Sherman sold 15,000 shares of common stock on October 1, 2026, at a weighted average price of $6.36 per share. The sales were made under a Rule 10b5-1 trading plan adopted December 18, 2025; prices ranged from $6.20 to $6.48. Sherman directly held 1,119,402 shares after the sale. A separate 2,000-share holding was reported indirectly through his son, and Sherman disclaimed beneficial ownership of those securities.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock, par value $0.0001 per share ("Common Stock") F1, F2 | 15,000 | $6.36 | $95K |
| holding | Common Stock F3 | -- | -- | -- |
Footnotes (3)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.
- F2. The price reported is a weighted average price. These shares were disposed in multiple transactions at prices ranging from $6.20 to $6.48. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares disposed at each separate price within the range set forth in this footnote.
- F3. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.